Travere Therapeutics is a commercial-stage company selling FILSPARI (sparsentan), approved for IgA nephropathy and FSGS, two rare kidney diseases, and Thiola for cystinuria.
Travere's case rests on sustained FILSPARI growth in IgA nephropathy and FSGS without nephrotic syndrome. Quarterly FILSPARI sales reached $200.2 million, supporting the commercial strategy, although patient start forms declined from the prior quarter. Pegtibatinase's HARMONY results are anticipated in 2H 2027; civorebrutinib adds longer-term potential with a U.S. IND submission planned by year-end. Cash supports execution, but continued losses and development spending leave funding discipline important.
Thesis checklist
0 risks need attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: FILSPARI keeps growing in both kidney diseases
Will continued sales growth be accompanied by firmer patient starts across IgAN and FSGS?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
FILSPARI sales accelerate, but fewer patient start forms merit attention
FILSPARI's dual IgAN/FSGS approvals anchor Travere's commercial thesis as competitive pressure and capital deployment test durability of the franchise
FILSPARI's dual IgAN/FSGS franchise anchors Travere's thesis; commercial uptake trajectory and competitive durability in both indications will determine if the story holds
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Kidney diseases, Rare genetic and metabolic diseases
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
9 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.